In May 2021 iStopMM reached an important milestone, with the publication of the first results of the screening study in its first article, “Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies” in the Blood Cancer Journal. In this first paper from the iStopMM trial, the methodology and the recruitment phase of the study was described in detail. The paper introduces the study to the scientific community and shows that the particiation rate is high enabling the study to reach its goals.
High prevalence of smoldering myeloma observed in nationwide screening study
December 16, 2021
In an article in CancerTherapyAdvisor.com the iStopMM study and it‘s results are covered. Results from the study were presented at the 2021 American Society of
